Scalper1 News
Gilead Sciences (GILD) is well-positioned in the growing hepatitis C drug market vs. rival AbbVie (ABBV), says an analyst in upgrading his Gilead stock rating. Matthew Harrison, an analyst for Morgan Stanley, raised his Gilead rating to overweight from equal weight. He also raised his price target on Gilead stock to 140 from 100. Gilead Sciences stock was up more than 3.5% in afternoon trading in the stock market today, above 97, and is up 30% for Scalper1 News
Scalper1 News